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Abstract 
 
 
Quorum sensing is a system that facilitates bacteria turning on and off gene expression 
depending on population density.  System 2 quorum sensing is utilized by both Gram positive 
and Gram negative bacteria, and the quorum sensing molecule used in this system is AI-2.  AI-2 
is biosynthesized by the enzyme LuxS from the precursor SRH.  This thesis describes an 
improved synthesis of SRH through the exploration of different protecting group strategies.  The 
knowledge gained from the improved synthesis of SRH is then applied toward the synthesis of 
SRH analogues with increased steric bulk installed through use of a stereoselective anti-
Mannich reaction.  SRH analogues with increased steric bulk are hypothesized to act as 
inhibitors of LuxS – with the ultimate goal decreasing the amount of AI-2 in the environment and 
therefore silencing gene expression dependent on system 2 quorum sensing.  
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Chapter 1: Introduction 
1.1 Quorum sensing and “soft antibiotics” 
Quorum sensing is a means of cell to cell bacterial communication by which colonies may 
coordinate behavior.  Individual bacteria send and receive chemical signals, called autoinducers 
(AI’s), to and from their surrounding environment. Bacteria use these chemical signals to assess 
population density and then, in response, regulate gene expression to initiate communal 
behaviors such as virulence, mobility, and bioluminescence. This process is initiated by an 
enzyme that produces a small molecule chemical signal, which is transported out of the cell. 
These AI’s accumulate in the environment until they reach a detectable level. A separate 
binding protein receives the AI and signals a pathway that ends in gene expression, as 
illustrated in Figure 1.1.  This chemical pathway controls a variety of behaviors in bacteria, 
ranging from bioluminescence in Vibrio fisheri and V. harveyi to pathogenicity in V. cholerae and 
Pseudomonas aeruginosa.1  
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Figure 1.1  Quorum sensing; the production and reception of chemical signals that can cause 
gene expression to regulate communal behaviors such as virulence, mobility and 
bioluminescence.   
 
Both V. cholerae and P. aeruginosa use quorum sensing to control group behaviors causing 
disease in human as well as a host of other pathogens.  Currently the only way to treat these 
bacterial infections is with traditional antibiotics, but resistance to these treatments is on the rise. 
When these infections are treated with commonly used antibiotics, all of the bacterial cells die 
except for those that have acquired genetic mutations to be resistant.  The only cells that 
survive and reproduce are resistant strains.  This treatment method creates extreme 
evolutionary pressure for widespread antibiotic resistance to develop.2 Thus, in order to combat 
antibiotic resistance, there is a need for not only new types of antibiotics but also for a new way 
to treat bacterial infections altogether.  One way to envision a new treatment method for 
bacterial infections is to interfere with quorum sensing pathways that turn on the expression of 
virulence factors.3  
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Targeting quorum sensing to combat antibiotic resistance has the potential to become a 
powerful new approach to treating bacterial infections. Bacteria use quorum sensing in order to 
conserve resources.4  Pathogenic bacteria that utilize quorum sensing for virulence expression 
remain dormant until there is a critical mass of cells, enough to do damage to the host’s immune 
system. Bacteria determine when they have reached this critical mass using quorum sensing 
communication to gauge their population density. 5  Therefore, if bacterial cells could be 
prevented from communicating with each other, this would keep them from initiating virulent 
behaviors against the immune system. A drug that served this purpose would be classified as a 
“soft antibiotic” because it would not kill the bacterial cells, just silence them.1 Although it would 
still be advantageous for bacteria to develop resistance to a soft antibiotic, since the drug is not 
lethal the bacteria would evolve to be resistant at a much slower rate.6    
  
There are a few possible routes that could be taken to prevent quorum sensing using a soft 
antibiotic:  the drug could prevent the bacteria from producing the AI (making the cells “mute”) 
(Figure 1.2a), or this new antibiotic strategy could stop the bacteria from receiving the chemical 
signals (making them “deaf”) (Figure 1.2b).		
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Figure 1.2  Possible routes to inhibit quorum sensing; a) inhibiting the production of autoinducer 
b) inhibiting the reception of autoinducer. 
 
1.2 Targeting system two quorum sensing  
Two different primary quorum sensing systems have been identified in the bacterial kingdom.  
System one quorum sensing refers to the communication within a species of bacteria, whereas 
system two quorum sensing refers to interspecies communication (Figure 1.3). Each system 
utilizes different classes of AI’s; therefore, each species of bacteria that engages in quorum 
sensing has a unique set of AI’s that they can differentiate in a complex chemical environment. 
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Figure 1.3  Two systems of quorum sensing; two different species of bacteria are denoted by 
color. 
 
In general, for system 1 quorum sensing, Gram-negative bacteria use N-acylhomoserine 
lactones (AHL’s) and Gram-positive bacteria use oligopeptides (AIP’s).  These systems allow 
bacteria to assess the population density of their own species, regardless of other species 
present in the environment.  When focusing on these intraspecies systems of communication, a 
quorum sensing inhibitor would have to be specifically tailored for each particular bacterial 
species.  This could be beneficial to the creation of soft antibiotics that specifically target a 
problematic bacterial population, while leaving harmless and beneficial bacterial communities 
unaffected.  However, the flipside of such selectivity is limited scope for each treatment.   
 
Bassler and coworkers identified a second quorum sensing system in 1994 – an overarching 
system of communication between species used by both Gram-positive and Gram-negative 
bacteria, known as system two.7  Autoinducer-2 (AI-2) is the signaling molecule used by this 
system. The enzyme that produces AI-2, LuxS, has been identified in roughly one third of 
bacterial genomes that have been sequenced (as of 2012), making it an excellent target for 
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research into broad quorum sensing inhibitors.8  Targeting interspecies communication could 
lead to the development of a broad-spectrum treatment for many kinds of bacterial infections, 
including P. aeruginosa (a common and harmful infection in cystic fibrosis patients) and V. 
cholerae (responsible for cholera upon infection of the small intestine).8 
 
The “parent” molecule for AI-2 is 4(S),5-dihydroxypentan-2,3-dione, DPD. DPD exists in many 
interconverting forms in aqueous solution; these molecules are collectively called AI-2.9 Figure 
1.4 shows those many forms and the binding proteins that have been determined to receive 
some of the AI-2 molecules in different bacteria. For instance, the R-THMF form of AI-2 
interacts with LsrB and turns on gene expression of pathogenic pathways in S. typhimurium, 
whereas the boron-ester S-THMF-borate is received by LuxP of V. harveyi bacteria and turns on 
a signaling pathway that goes through LuxQ to turn on gene expression of bioluminescence.8 
 
 
Figure 1.4 Known forms of AI-2 and the proteins with which they are associated in S. 
typhimurium & V. harveyi. 
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The biosynthesis of AI-2 is shown in Scheme 1.1; it begins with S-adenosylmethionine (SAM).  
SAM is a common cofactor in bacterial cells, known to be a methylating agent, and in the 
biosynthesis of AI-2, the first step is conversion of SAM into S-adenosylhomocysteine (SAH) – a 
derivative lacking the methyl group.  This transformation is mediated by a methyltransferase 
(Mtf) enzyme.  The next step in the biosynthesis of AI-2 is the removal of the adenosyl moiety 
from SAH to form S-D-ribosyl-L-homocysteine (SRH), the immediate precursor to AI-2.  SRH is 
converted to homocysteine (HCys) and DPD / AI-2 by LuxS. 
 
Scheme 1.1  Biosynthesis of DPD / AI-2. 
 
 
There are a variety of system two quorum sensing inhibitors reported in the literature. The 
molecules shown in Figure 1.5 are representative of how structurally different molecules can 
inhibit the same quorum sensing system, and by different mechanisms.10  The inhibitory activity 
of such compounds is assessed through a variety of biochemical assays, often including the 
measurement of bioluminescence and biofilm formation inhibition.  SRH analogs inhibit the 
LuxS enzyme by competitively binding in the active site of LuxS in lieu of SRH.11,12 Immucillin A 
analogs target the precursor of LuxS by tightly, but not covalently, binding to MTAN, the enzyme 
that converts SAH to SRH (Scheme 1.1).13 Cinnamaldahyde and its derivatives inhibit quorum 
sensing activity by decreasing the binding ability of the transcriptional regulator LuxR to its 
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promoter sequence.14,15 Brominated furanones inhibit system two quorum sensing by covalently 
binding to the nucleophilic cysteine residue in the active site of LuxS, causing inactivation of the 
enzyme.16  For this project we have focused our energy on studying the inhibition of the LuxS 
enzyme by way of creating analogs of SRH, the precursor of DPD / AI-2. 
 
 
Figure 1.5 Examples of system two quorum sensing inhibitors. 
 
1.3 Designing novel SRH analogs as LuxS competitive inhibitors 
For multiple reasons, LuxS appears to be a good quorum sensing inhibition target for a soft 
antibiotic.  First, because LuxS is both the final enzyme in this biosynthetic pathway and unique 
to the production of AI-2, its inhibition would have a small effect on the other metabolic 
pathways in the bacteria.  Interference with other metabolic pathways could be harmful to the 
bacteria creating additional evolutionary drive to become resistant. This is not the case for the 
inhibition of Mtf or Pfs; because both enzymes are also a part of the activated methyl cycle 
(AMC), the metabolic pathway responsible for recycling SAM in the cell,17 their inhibition would 
likely affect other metabolic cycles that use SAM.  Secondly, there is no analogous enzyme to 
LuxS in humans;18 thus, if a LuxS inhibitor was found and developed to treat bacterial infections 
in humans, it should not inhibit any important enzymatic pathways in the patient, reducing the 
potential for side effects.  If it were possible to inhibit the LuxS enzyme using a small molecule, 
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such a drug would effectively cut the production of DPD / AI-2 in the bacterial environment, no 
matter the population density, making the cells “deaf” to the presence of others.   
 
The design of a good LuxS inhibitor relies on understanding the mechanism of catalysis for the 
SRH à DPD / AI-2 transformation.  With this information in hand we can rationally design a 
potent inhibition strategy. 
 
1.3.1 LuxS structure and mechanism 
LuxS, the enzyme that catalyzes the cleavage of SRH to DPD and homocysteine, is a 
homodimeric metalloenzyme dependent on Fe2+.  The active site exists at the interface of the 
two monomers in the dimeric form; as such the catalytic abilities of LuxS appear to be 
contingent on dimerization of the enzyme.  Three conserved amino acids in the active site, two 
histidine residues and a cysteine residue, coordinate the iron cation.19  The crystal structure in 
Figure 1.6 depicts LuxS in its dimerized form, to which ligand SRH is bound before catalysis.   
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Figure 1.6 Crystal structure of LuxS dimer; monomers shown in separate colors (pink and 
green), each monomer is bound to SRH in active site (shown in red and yellow).20 
 
The catalytic mechanism of LuxS has been elucidated by Pei and coworkers21 and is pictured in 
Scheme 1.2.  The closed ring form of SRH binds to the active site, whereupon LuxS catalyzes 
ring opening to aldehyde 1 via coordination with the metal ion and loss of water.  The proton at 
C2 is abstracted by the cysteine 84 residue creating an enolate 2.  Cysteine 84 then donates a 
proton for tautomerization forming a ketone at C2 (3).  The same cysteine residue then 
deprotonates C3, generating another enol (4), which is followed by subsequent tautomerization 
to form a ketone at C3 (5).  Finally, facilitated by the abstraction of the proton at C4 to first form 
another enolate (6), the sulfur-carbon bond is cleaved to form homocysteine and 7 via β-
elimination; an additional spontaneous tautomerization yields DPD. 
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Scheme 1.2 Catalytic mechanism of LuxS on SRH21 
 
 
1.3.2 Inhibition assay for LuxS  
There is a biochemical assay that assesses the inhibition of LuxS called the Ellman’s Assay 
(Scheme 1.3). Ellman’s assay uses 5,5’-dithio-bis(2-nitrobenzoic acid) (DTNB) to convert HCys 
into its disulfide conjugate 9. The byproduct of this reaction, 2-nitro-5-thiobenzoate (8), is yellow 
in color, and its absorbance is measured at 412 nm. The production of 2-nitro-5-thiobenzoate 
(8) occurs at a 1:1 ratio with the production of DPD.  Thus, measuring the concentration of 2-
nitro-5-thiobenzoate (8) indirectly measures AI-2 concentration, effectively measuring quorum 
sensing.22 
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Scheme 1.3 Ellman’s assay. 
 
Ellman’s assay is an in vitro assay, meaning that the assay is performed outside of the bacterial 
cell using purified enzyme.  In the absence of an inhibitor LuxS remains active, which can be 
measured by the production of yellow dye as described above.  We can see this in the positive 
control of the assay shown in Figure 1.7. The addition of a competitive inhibitor to the Ellman’s 
assay results in a decrease in the activity of LuxS, which can be quantified 
spectrophotometrically. For example, the compound L-nitroarginine methyl ester hydrochloride 
(L-NAME) was identified as a possible LuxS inhibitor using computational screening, and it 
decreases LuxS activity in a dose-dependent manner in vitro as determined by the Ellman’s 
assay (Figure 1.7).  This research was performed by another member of our group, Keeshia 
Wang, and the discovery of this inhibitor is laid out in her thesis,	 ‘Biochemical Assay 
Optimization and Computational Screening Efforts to Identify Potential LuxS Inhibitors’.23 
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Figure 1.723   LuxS inhibition assay of L-nitroarginine methyl ester hydrochloride (L-NAME). LSI 
= LuxS + SRH + Inhibitor (L-NAME).  Columns are produced from the slope of inhibition in each 
assay; they are run in triplicate and error bars show the standard error of those trials.    
 
1.3.3 Experimental design 
There is a need for a robust synthesis of SRH in the pursuit of LuxS inhibitors for two reasons.  
The first is that high-quality SRH must be added to the Ellman’s assay of any potential LuxS 
inhibitor to determine whether another small molecule can compete with it to prevent AI-2 
production. With chemically synthesized material, it should be easier to control for quality and 
purity of SRH stock with easy quantification and characterization. Additionally, it is necessary to 
have a reliable synthesis of SRH for the purpose of developing a skillset on which to build in 
order to prepare analogs of SRH as potential LuxS inhibitors in the laboratory.  A synthesis that 
is robust would be able to accommodate structural modifications, i.e., addition of alkyl groups, 
providing SRH analogs of the type(s) shown in Figure 1.8. 
 
Figure 1.8 Proposed alkylated SRH analogs. R1, R2 = H, alkyl, aryl. 
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The active site of LuxS is at the interface between the two halves of the dimer and the 
mechanism of action is such that the transformation takes place only when LuxS is in its 
dimerized form. We propose that the bulky R groups of the proposed inhibitors will restrict the 
interaction between the two halve and will interfere with the dimerization of LuxS.  Therefore, it  
inhibit the enzymes ability to catalyze the formation of DPD from SRH, given that the active site 
requires formation of the dimer.   
 
In chapter 2 I will review the synthesis of SRH; both from the classic ways SRH was 
synthesized in the literature and from research carried out in our lab that allows us to synthesize 
highly pure crystalline SRH to use in assays.  Chapter 3 goes over the progress toward making 
an SRH analogue modified with an R group at the C3 position using some of the lessons 
learned from our SRH efforts.   
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Chapter 2: Preparing Homocysteine Derivatives with Diverse Protection Strategies in the 
Chemical Synthesis of SRH 
 
SRH is the precursor of the bacterial quorum sensing molecule AI-2 and the substrate of the 
enzyme LuxS, a target for “quorum quenching,” or quorum sensing inhibition.  It is necessary to 
have access to the molecule SRH in a high-purity, quantifiable manner for the inhibition assay 
run in our lab.  It is also necessary to have a robust synthesis of SRH that can handle 
modifications in order to produce SRH analogs.  Outlined in this chapter are the synthetic 
approaches to producing SRH and the modifications utilized in our lab to make this synthesis 
more reliable and robust.   
 
2.1 Synthetic approaches to SRH 
There are two literature precedents for the chemical synthesis of SRH. The first, developed by 
Guillerm and Allart in 1991, uses a tosylated ribose derivative (12) as the electrophile and L-
homocysteinate as the nucleophile in an SN2 reaction to couple the moieties (Scheme 2.1)24. 
This synthesis was designed to prepare SRH for use in an assay that required radiochemically 
pure SRH labeled at the ribose C5 position (14).  Four steps are required to access starting 
material 10, giving a total of 8 steps and a 5% yield overall.  Since this overall yield is very low, 
and since the need for a radiolabel is not typical, synthesis of unlabeled SRH could be 
envisioned in a number of ways. 
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Scheme 2.1 Guillerm and Allart synthesis of SRH, 1991.24 
 
In 2003, Zhou and coworkers developed a route to SRH that starts from a protected derivative 
of L-homocystine (20, Scheme 2.2) in which the carboxyl group is protected as a methyl ester 
and the amine group is protected as a tert-butylcarbamate (Boc).25  In a one-pot reaction, 
disulfide 17 is reduced to form the homocysteine derivative. The resulting thiol is coupled to a 
protected ribose moiety (18) using a Mitsunobu-type reaction that afforded the product 19 in 50-
70% yield.  This convergent synthesis allows for access to SRH in 45% yield following global 
deprotection accomplished over three steps.    
 
Scheme 2.2 Zhou synthesis of SRH, 2003.25 
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The coupling between 17 and 18 as reported by Zhou and coworkers was attempted in our 
laboratory; however, analysis of crude reaction mixtures by NMR and TLC consistently showed 
decomposition of starting material and no formation of product.26  To investigate this problem, 
the transformation was broken down into two individual steps: first, the reduction of disulfide to 
thiol, and second, the coupling of the homocysteine moiety to the ribose moiety. When 
attempted separately, the reduction of disulfide 17 in the presence of tributylphosphine was 
completed to full conversion (shown by a nearly quantitative yield after column chromatography 
and characterization of product via 1H NMR), suggesting that the failure of the reported 
Mitsunobu-type coupling reaction was likely due to inefficient nucleophilic substitution to replace 
the hydroxyl group on 18 with the thiol to form the necessary C-S bond of 19.26  This reaction 
could have failed for several reasons.  One could be failure to activate the hydroxyl group on 18 
as an electrophile and another could be failure of the reaction conditions to deprotonate the thiol 
to the more nucleophilic thiolate.   
 
To address the electrophile, a solution was inspired by Wnuk’s synthesis of an SRH analog (25, 
Scheme 2.3) in which a sulfonyl activating group was added to the ribose moiety (22) to convert 
the hydroxyl into a better leaving group (see 23) and an SN2 reaction was employed using an 
unprotected R/L-homocysteine moiety (HCys) and sodium hydroxide as the base to form the 
thiolate.27 As seen in the revised reaction scheme for SRH (Scheme 2.4), a tosylate was 
therefore appended to the ribose moiety. 
 
	 18 
Scheme 2.3 Synthesis of SRH analog employing an SN2 reaction using either mesylate or 
tosylate as a leaving group on the ribose moiety as explored by Wnuk and coworkers.27 
 
 
As seen in Scheme 2.3, no protection group is used on Hcys prior to the coupling reaction.  For 
our purposes it seemed prudent to protect Hcys so we could use a strong enough base to 
ensure thiolate production; indeed this strategy is employed by Wnuk for the synthesis of an 
SRH analog, S-(5-deoxy-D-xylofuranos-5-yl)-L-homocysteine (SXH).27 The protection strategy of 
Boc and tert-butyl (t-Bu) ester used on the homocysteine moiety was chosen (see 26) for easy 
one-step removal at the last stage of the synthesis (conversion of 30 to SRH•TFA).  Outlined in 
Scheme 2.4 is the two coupling partners chosen for our synthesis of SRH (27 and 29) as well as 
the continued synthesis of SRH that was carried out. This synthesis, initially developed in our 
laboratory by Ruoyi Liu26, was successfully reproduced through to the desired product, the 
trifluoroacetic acid (TFA) salt of SRH, with the yields shown.  
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Scheme 2.4 Revised synthesis of SRH 
 
The synthesis outlined in Scheme 2.4 does reliably produce the desired product SRH.TFA salt 
and was straightforward enough for me to reproduce at the very beginning of my grad school 
career.  It can be completed in just a few days and overall is a friendly synthesis. This synthesis 
does have some drawbacks, however, including low yields in the coupling reaction, 
comparatively high cost of the L-homocystine starting material (15), and the necessity of tedious 
column chromatographic purification for most intermediates. Using the base BuLi for the 
deprotonation of thiol 27 may be excessive and a gentler option could be safer and lead to 
fewer byproducts.  For these reasons, an altered/optimized synthesis was explored.    
 
2.2 Thioether bond formation: drawbacks and optimization 
The low yield of the coupling reaction producing the thioether bond of SRH (30, 18% over 2 
steps) is a major drawback to the synthesis shown in Scheme 2.4.  Using an excess of 
homocysteine moiety 27 and using ribose moiety 29 as the limiting reagent can improve the 
yield of the coupling reaction as shown by Ruoyi Liu;26 this synthetic strategy is also employed 
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by Zhou and coworkers.25 However, considering that homocysteine derivative 27 is costly and 
that ribose derivative 29 is inexpensive and easy to prepare, this approach seems suboptimal in 
both yield and cost. Also, the homocysteine derivatives that are planned for the synthesis of 
SRH analogs will require multiple synthetic steps and using them in excess may not be an 
option.  
 
Optimization of the C-S bond formation using homocysteine moiety 27 as the limiting reagent 
could make the acquisition of SRH for biochemical assays more efficient.  In addition, this 
strategy could help achieve a more systematic understanding of the requirements for the 
leaving groups and the protecting groups as well as the reaction conditions appropriate for an 
efficient synthesis of SRH. The resulting convergent synthesis would allow access to SRH 
analogs with modification at the homocysteine moiety, ribose moiety, or both. This is important 
to establish key principles for a unifying inhibitor synthesis strategy. 
 
2.3 The homocysteine moiety protecting groups 
 
In order to synthesize the homocysteine nucleophile, both the acid and amine functional groups 
of L-homocystine need to be protected (31), and then the molecule is reduced to its 
corresponding thiol (32, Scheme 2.5). 
 
Scheme 2.5  Synthesis of the homocysteine moiety.  
 
Each protecting group must be stable to basic conditions since the subsequent coupling 
reaction is mediated by a base to form the thiolate nucleophile (Scheme 2.4).  Prior work by 
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Ruoyi Liu suggested that the protecting groups on homocysteine moiety 32 have a distinct 
influence on the success of the coupling reaction.26  In her hands, SN2 coupling of t-Bu / Boc 
protected homocysteine derivative 32 with ribose electrophile 29 proceeded in good yield (70%) 
using n-butyllithium, a strong base, in DMF. However, the identical attempted coupling using a 
p-methoxyphenyl (PMP) protected amine was unsuccessful, perhaps due to steric bulk. 
Therefore, I was interested in determining which base-stable protecting groups at both the acid 
and amine positions of HCys would allow for the most efficient synthesis.  To determine this I 
set out to synthesize a library of protected homocysteine derivatives to be screened in the 
coupling reaction.  With these results on hand, routes to SRH analogs can employ any of the 
successful protecting strategies identified.  
 
Two series of protected L-homocystine derivatives were prepared: those that maintained Boc 
protection on the amine group and varied the protection of the carboxylic acid (2.3.1) and those 
that maintained t-Bu protection on the acid group and varied the protection of the amine (2.3.2). 
 
2.3.1 Protecting the carboxyl group 
A system was put in to place to test various carboxyl protecting groups. Boc was used as the 
amine protecting group in all cases, both because it is the precedent in the literature25 and since 
it had been previously demonstrated to be compatible in the coupling reaction in our hands 
(Scheme 2.4).26 The preparation of Boc protected homocysteine (33) is a straightforward 
synthesis (the first step in the conversion of 15 à 26; see Scheme 2.4) that can be run 
overnight; it yields a white solid that requires no additional purification.  Different acid protecting 
groups were chosen based on their variety of steric impacts, together with the level of difficulty 
to synthesize and purify as well as their stability as homocystine intermediates (Scheme 2.6). 
Ideally what we would be looking for in a synthesis would be high yields and crystalline 
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substrates that could be purified through recrystallization or trituration, thereby negating the 
need for column chromatography. 
 
Scheme 2.6 Synthesis of a series of homocystine derivatives with varying carboxylic acid 
protecting groups. 	 		
 
In a previous synthesis of methyl ester 17 conducted in our laboratory,28 the compound was 
formed over two steps, using thionyl chloride and methanol to form 16 and then was carried 
through to the fully protected substrate 17 using (Boc)2O to protect the amine.  This procedure 
yielded a crystalline substrate that was stable at room temperature for greater than ten 
months.28 To round out the series of differences in steric bulk between methyl and t-Bu esters, 
ethyl and iso-butyl esters 34 and 35 were initial targets.  Additionally, to have the option of 
additional deprotection strategies as well as differences in steric bulk and electronics, an 
aromatic benzyl protecting group (which can be removed later through hydrolysis) was also 
added to the carboxylic acid (36). All three of these targets were accessed through a parallel 
synthetic strategy: ethyl-, iso-butyl- and benzyl- protected homocystine derivatives 34, 35, and 
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36 were synthesized from Boc protected homocystine 33 using the corresponding chloroformate 
and catalytic DMAP.29  The yields of these reactions were moderate and sufficient for our needs 
(i.e., >50%) with the exception of ethyl derivative 34 (27%).  These reactions were run 1-2 times 
each and as such were not optimized for improved yields. Importantly, all compounds were 
either crystalline or powdery solids upon purification by recrystallization from hot ethanol. 
Recrystallization has an advantage over flash column purification because desired compounds 
can be acquired in much purer form and in a shorter amount of time and without using as much 
solvent.  Moreover, these recrystallized solids were very easy to work with for subsequent 
synthetic steps, and tended to last for several months when stored refrigerated.  This is major 
benefit when working with these substances, as being able to keep these intermediates on hand 
greatly facilitates the preparation of SRH for LuxS inhibition assays when the need arises.  This 
workup and purification optimization will also be helpful when working to produce SRH analogs. 
 
2.3.2 Protecting the amine group 
For the series of amine protecting groups, t-Bu ether was chosen as the standard carboxyl 
protecting group, again due to its previously demonstrated compatibility in the SN2 preparation 
of the SRH thioether.26,30 The protecting groups chosen for the α-amine are common amino acid 
protecting groups, selected for their range of bulkiness, electron withdrawing properties, and 
aromaticity (Scheme 2.7).  
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Scheme 2.7 Synthesis of a series of homocystine derivatives with varying amine protecting 
groups.   
 
Cbz, Troc and Fmoc derivatives 37, 39, and 41 were synthesized using the corresponding 
chloroformates. The t-butyl group was added, using tert-butyl-2,2,2-trichloroacetimidate, without 
purification of the intermediate31, and the final products (38, 40, and 42) were easily purified 
using silica gel flash column chromatography.  Yields were moderate to good (>50%) and the 
oils were stable with refrigeration (> 1 month).   
 
2.4 Results of coupling reactions 
Our initial conditions for the coupling reaction were based on that reported by Wnuk, shown 
above in Scheme 2.4, which uses DMF as a solvent with a lithium base.27 There are a few 
drawbacks to the use of DMF as a solvent in this case.  Due to DMF’s high boiling point and 
miscibility with both organic solvents and water it is notoriously difficult to remove during 
workup.  Moreover, there is a possibility of DMF acting as an electrophile, which could result in 
formylation and lead to off-route byproducts. (The formylation with DMF as the electrophile is 
known as the Bouveault aldehyde synthesis.32) It was also difficult for us to keep DMF rigorously 
dry under our laboratory conditions, so we explored additional solvents, and the more 
appropriate polar aprotic solvent THF was chosen.28 
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As noted above (Scheme 2.4) the original coupling reaction uses n-BuLi as the base to 
deprotonate the thiol. n-BuLi is a very harsh base that has the to potential to decompose 
starting material during the reaction and is not easy to work with.  Therefore we were interested 
in screening for milder conditions.  The pKa of a thiol is around 10; however, the pKa of the 
conjugate acid of n-BuLi is about 60, making this base much stronger than necessary to remove 
the proton from the thiol functional group.  Therefore, the use of milder amide bases was 
explored, whose pKa of their conjugate acids are between 10 and 40, see table 2.1.  This range 
should give us more insight into the necessary conditions of the coupling reactions.   
 
Our research team used commercially available propyl iodide to test each electrophile in the 
model reaction shown below (Table 2.1). It was found that potassium bis(trimethylsilyl)amide 
(KHMDS) worked best to give the cleanest conversion and highest yield of product. 30 
 
Table 2.1 Model coupling reaction for evaluation of bases. 30 
 
Base Conjugate acid pKa Conversiona Product ratioa 
DIPEA 10.033 0% n/a 
DBU 16.834 100% 4:1 
KHMDS 25.835 100% 19:1 
LDA 35.736 Not interpretable Not interpretable 
a Determined by analysis of δ 2.58 (m, 2H; X), δ 2.51 (m, 4H; X), and δ 2.69 (m,  2H; X) signals 
of crude proton NMR spectra.   
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With these milder conditions in hand, the library of protected homocystine compounds (see 
section 2.3) were reduced to compound 32, using the same conditions depicted in Scheme 2.4 
for the reduction of 26 to 27, and coupled to protected/mesylated ribose 43.  The results of the 
coupling reactions carried out by team member Brendan Corcoran are shown in Table 2.2.37 
 
Table 2.2 Results of coupling reaction. 
 
Compound PG1 PG2 Result 
44a t-Bu Boc 46% 
44b Me Boc 5.5% 
 
The only additional coupling reaction that yielded product used the methyl ether protected 
coupling partner 17 to produce 44b in 5.5% yield.  Coupling reactions using the other 
homocystine derivatives (34-36, 38,40 and 42) had little to no yields and many co-eluted with 
unreacted starting material as well as disulfide byproduct.  Though giving less than satisfactory 
results, these experiments did validate some of the previous research carried out in our 
laboratory by providing additional examples of the unexpected sensitivity of this coupling 
reaction.  Some possible reasons for the failure of these coupling reactions may be due to 
sensitivity of the carboxyl protecting groups to base; the tertiary center on the protecting group 
may be necessary to avoid base-mediated cleavage of the protecting groups.  Additionally, 
deprotonated thiols have a greater potential to oxidize than their protonated counterpart and any 
increase in time or oxygen in reaction flask could result in generation of disulfide byproduct.   
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2.5 The improved route to SRH 
With the results of the protecting group screen in hand, in addition to the improved reaction 
conditions, we developed an efficient route to SRH•TFA (Scheme 2.8).30 In this synthesis 
SRH•TFA is produced from L-homocystine in 26% yield over 5 steps and utilizes the t-Bu ester 
and Boc protecting groups on the thiol coupling partner (27).   
 
Scheme 2.8 Improved synthesis of SRH. 30 
 
 
This is improved over previous syntheses due to the increased overall yield over fewer and 
gentler synthetic steps, and its utilization of traditional column chromatography only once.  This 
method gives increased reliability over known methods giving access to high quality SRH for 
biochemical assays testing the inhibition of LuxS.  This route serves as a great jumping off point 
for the synthesis of SRH analogs.    
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Chapter 3:  Progress Towards the Synthesis of Alkylated Homocysteine Derivatives for 
the Synthesis of SRH Analogs  
 
As discussed in the introduction (Chapter 1), the manipulation of quorum sensing has the 
potential to make a broad impact on the medical world.  Antibiotic resistance is becoming a 
larger problem and new and possibly milder treatments for bacterial infections, such as quorum 
quenching, are in demand.1 Targeting LuxS as the enzyme to inhibit in the development of a 
soft antibiotic is advantageous because it has been identified in many different types of bacteria, 
and therefore its inhibition could lead to the development of broad spectrum antibiotic 
treatments.  Furthermore, LuxS is responsible for the final enzymatic transformation in the 
production of AI-2, so its inhibition will not interfere with other pathways – making the results of 
inhibition easier to interpret because there are fewer factors to consider.  One possible 
mechanism of inhibition is utilizing analogs of the LuxS substrate that will compete with the 
substrate for binding, but not be converted into the product.  This approach is known as rational 
design.38 
 
3.1 Proposed analogs of SRH and retrosynthetic plan 
There are many analogs of SRH reported in the literature that inhibit the activity of the LuxS 
enzyme.39  Some examples of these compounds are shown below (Figure 3.1).  SRH analog 45 
published by Pei and coworkers12 as well as 46 and 47 published by Zhou and coworkers11 
show competitive dose-dependent inhibition of LuxS.  Meanwhile, 48, 49 and 50 published by 
Wnuk and coworkers27,40 show time-dependent inhibition of LuxS. 
 
	 29 
 
Figure 3.1 Examples of SRH analogs reported in the literature as LuxS inhibitors. 
 
Since the vast majority of the published SRH analogs are altered on the ribose moiety, we were 
interested in exploring whether or not inhibition could be achieved by altering the homocysteine 
moiety.  Such analogues could competitively bind to the active site of one LuxS monomer while 
sterically blocking the association of the second monomer from dimerizing into its active form.  
We envisioned accomplishing this by appending an alkyl group to C-3 or C-4 (51, Figure 3.2) of 
the homocysteine moiety of SRH. Figure 3.2 shows possible SRH analogs that follow this 
description (51a-f). 
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Figure 3.2 SRH analogs envisioned as possible LuxS inhibitors.  
 
The proposed retrosynthetic analysis of 51 begins with a disconnection between the sulfur and 
C-5, which in the forward sense would utilize the same coupling reaction previously optimized 
for the synthesis of SRH (Scheme 3.1).30 Ideally, for protecting groups on 53, the amine and the 
carboxylic acid would be Boc and t-Bu, respectively, as prior investigations into the chemical 
synthesis of SRH demonstrated very little coupling ability when other protecting groups were 
used (Chapter 2).  From here, we envisioned accessing the appropriate homocysteine 
derivative from imine 57 and ketone 56.  In the forward direction, compound 55 could be 
acquired stereoselectively through the use of a stereoselective Mannich reaction catalyzed by L-
proline.41  
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Scheme 3.1 Retrosynthetic analysis of proposed SRH analog.  
 
The Mannich reaction affords β-amino ketones or aldehydes, known as “Mannich bases”.  
Traditionally, first an iminium ion (60) is formed from condensation of a ketone (58) and an 
amine (59).  This iminium ion (60)  then acts as an electrophile, and is attacked by an enol (61)  
to form a new C-C bond (62).42 The first report of the Mannich reaction was in 1903, and was 
formation of tertiary amine from acetophenone, formaldehyde, and ammonium chloride43 – over 
a decade before Mannich would recognize that this was a general reaction with wide scope for 
the amine, and carbonyl compounds – resulting in this reaction bearing his name (Figure 
3.2a).44 Over the next century, many variations and improvements to the Mannich reaction were 
made to expand the scope even further.  One such variation is the use of proline (66) as an 
enantioselective catalyst.45 Proline (66) allows for the Mannich to be a rare example of an 
asymmetric and catalytic multi-component reaction (Figure 3.2b). 46  Relevant to this work, 
proline (66) has been shown to be an effective catalyst to form α-functionalized amino esters in 
α stereo-enriched manner (68), but requires ethyl glyoxylate (65) to be preformed as an imine.47 
The ethyl glyoxylate imine derivative (65) can then act as an electrophile with a variety of 
enolates (61) in the presence of proline (66) to give a synthetic intermediate en route to SRH 
derivatives. 
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Scheme 3.2 (a) A generic Mannich reaction and (b) an enantioselective proline catalyzed 
Mannich reaction with preformed imine intermediate. 
  
(a) 
 
(b) 
 
 
 
3.2 A Mannich-based approach to the preparation of alkylated homoserine  
Previously in our laboratory, a Mannich-based approach was used in attempt to access 
analogues of SRH.26  In this approach, L-proline (66) was utilized as a catalyst for the Mannich 
reaction48 and a moderate yield was obtained (see Scheme 3.3).  Over the course of five 
additional steps, the Mannich product 71 was converted into a reduced homocysteine moiety 
72.  With this homocysteine derivate in hand, all attempts to couple the ribose moiety (43) to 
form 73 failed, likely due to incompatibility of the protecting groups in the homocysteine 
derivative with the coupling reaction.  
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Scheme 3.3 Previously attempted synthesis of protected SRH analog 73.26 
 
Another route to access coupling partner 53 involves the synthesis of (2S,3R,4S)-4-
hydroxyisoleucine, published by Wagner and co-workers, in which they report the production of 
final compound (78) at a 22% overall yield on a scale of 80 grams (Scheme 3.40).49   
 
 
Scheme 3.4 Synthesis of (2S,3R,4S)-4-hydroxyisoleucine as published by Wagner and co-
workers.49 
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3.3 Extension of the Wagner synthesis to alkylated homocysteine derivatives 
The protecting groups utilized in the Wagner synthesis (Scheme 3.4) are ethyl ester for the acid 
and PMP for the amine.  Previous work (Chapter 2) suggests that this combination of protecting 
groups is not compatible with the coupling reaction to attach the ribose moiety.  However, as 
Wagner’s synthesis could be performed on large scale from relatively inexpensive substrates, 
use of this synthesis to acquire compound 78 is still advantageous even though it requires 
switching the protecting groups prior to thioether formation as depicted in Scheme 3.5. 
 
Scheme 3.5 Switching to protecting groups compatible with coupling reaction. 
 
 
For reasons stated above (3.1) we envisioned creating steric bulk at the R1 and R2 positions of 
51.  This was done by first exploring the expansion of R2 using a variety of commercially 
available ketones.  The synthesis of compounds 75, 83, and 84 starts with known imine 69,50 
the preparation of which was carried out in quantitative yield on a large scale (i.e., 8 g) from p-
anisaldehyde and 82, with no purification required. The PMP-protected imine (69) was reacted 
with various commercially available ketones utilizing a stereospecific L-proline catalyzed 
Mannich reaction49 to produce intermediates 75, 83, and 84 (Scheme 3.6). The syntheses of 75 
and 83 were carried out with 44% and 46% yields, respectively, after flash column purification. 
The production of compound 84 under the same conditions was confirmed via 1H NMR analysis 
of the crude product mixture, but was not isolated due to low yield.  
 
Intermediate 75 was taken forward to the subsequent reactions while 83 and 84 were not. 
Compound 75 was epimerized to 76, then recrystallized from ethanol, resulting in the recovery 
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of white delicate crystals in 33% yield.  Interestingly, Wagner reports using no purification of the 
Mannich product 75 prior to epimerization, but when crude 75 was carried forward in our hands, 
the unpurified 75 did not epimerize but rather yielded a mix of isomers as a thick brown oil, 
rendering purification via recrystallization not feasible. Even after the use of column 
chromatography during this step, the product was a yellow oil, rendering the recrystallization 
quite difficult. 
 
Scheme 3.6 Mannich reaction of imine with various commercially available aldehydes and 
epimerization of column purified 75. 
 
 
Wagner describes a one-pot deprotection of the amine and reduction of the ketone using 
(NH4)2S2O8 and a catalytic amount of CAN to accomplish the deprotection, then adding 
potassium borohydride and CeCl3 and a chelating agent to complete the reduction; this method 
was unsuccessful in our hands (Scheme 3.7a). Decoupling the amine deprotection from the 
carbonyl reduction was then the logical progression for troubleshooting this transformation.  
Cleavage of the PMP group of 76 to reveal the free amine (88) using CAN as a catalytic oxidant 
was successful with an isolated yield of 26% (Scheme 3.7b).  Building from our findings in the 
SRH synthetic optimizations (Chapter 2, Scheme 2.8), a Boc-protecting group on the amino 
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of the SRH thioether. However, when attempting to install the Boc protecting group on 
compound 89 starting material was consumed but no product was formed.  Crude proton NMR 
spectroscopy showed various decomposition products, none of which were isolated or further 
characterized.  
 
Scheme 3.7 a) Unsuccessful one-pot deprotection and reduction if the carbonyl.  b) Removal of 
PMP protecting group and failed addition of Boc. 
 
(a) 
 
 
(b) 
 
 
This unsuccessful transformation inspired the creation of a new route to the Boc protected 
homocysteine substrate. 
 
3.4 Alternate in situ preparation of Boc protected intermediate   
The unsuccessful conversation of 88 à 89 as shown above necessitates direct access of the 
homocysteine moiety (Scheme 3.8) with Boc-protection on the amino group. However, the 
corresponding Boc-imine 91 is inherently reactive, making it very sensitive to moisture.51 This 
drawback can be overcome by producing the Boc-imine 91 in situ, with the subsequent Mannich 
reaction immediately carried out in the same pot (Scheme 3.8).51 To this end, α-amido sulfone 
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90 was prepared from t-Bu carbamate, ethyl glyoxylate, and sodium p-toluenesulfinate and was 
easily recrystallized from water as white solid with a 40% yield.52  Reaction to produce 91 was 
initially attempted with L-proline as the catalyst to give the (S,S) enantiomer, but this was 
unsuccessful.  Using the modified catalyst reported by Melchiorre and shown in Scheme 3.8,51 
the reaction was carried out on a 200 mg scale and proceeded with a yield of 77% of the anti-
Mannich product 92 after purification by column chromatography. The modified catalyst allows 
access to the desired (S,R) enantiomer in a single step and was successful in this reaction and 
negates any need for epimerization.  The modified catalyst’s ability to catalyze this coupling 
reaction over proline is likely due to decreased steric interactions in the transition state.  It is 
presumed that the reaction proceeded with the stereoselectivity reported.51  
 
Scheme 3.8 Synthesis of Boc-protected precursor to alkylated homoserine/homocysteine. 
 
 
3.5 Future directions 
In keeping with previous observations regarding the sensitivity to protecting groups 
demonstrated in the SN2 formation of the thioether bond of SRH, it is necessary to switch out 
the ethyl ester protecting group of compound 92 for a t-Bu ester (94).  A saponification can 
easily be carried out with lithium hydroxide to produce the free acid and a t-Bu ester protecting 
group can be added with either tert-butyl-2,2,2-trichloroacetimidate31 or t-Bu chloroformate29 
(see Chapter 2, Scheme 2.7).  The aldehyde functionality of 94 could then be reduced to 
produce alcohol (95) with sodium borohydride, and then converted into mesylate 96.  The 
mesylate, a good leaving group, can then be displaced via an SN2 reaction with potassium 
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thioacetate to form the C-S bond in 97.53  From 97, the acetate protecting group can be cleaved 
to reveal a thiol group of 9854 that can be directly coupled with ribose derivative 43 to afford 
protected SRH analogs 99, which could be purified and isolated as TFA salt 100.  
 
Scheme 3.9 Proposed transformation of Mannich product 92 to SRH analog 100 
  
 
The reduction of the aldehyde and subsequent reactions to produce the thiol coupling partner 
were successfully completed by a previous member of our lab on the Et/Boc protected 
homocysteine derivative.26  The only trouble came about when the coupling reaction to the 
ribose moiety took place.  Through the extensive study of necessary protecting groups and 
optimized coupling reaction conditions (Chapter 2), coupling partner 98 is much a much more 
likely candidate for successful coupling and completion of SRH analog 100. 
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Chapter 4: Experimental 
 
General Methods. Unless otherwise indicated, all reagents were of research grade or finer and 
were used without further purification. Methanol was distilled at reflux from magnesium and 
iodine. Anhydrous solvents dichloromethane, ethyl ether, toluene and tetrahydrofuran (THF) 
were obtained from a glass contour solvent system (SG Water USA, LLC). Air- and water-
sensitive reactions were carried out in oven-dried glassware under a dry argon atmosphere. 
Flash column chromatography was carried out with Sorbent Technologies 60 Å (500-600 Mesh) 
silica gel.  Thin layer chromatography (TLC) was performed using Sorbent Technologies silica 
gel UV254 (200 µm layer) plates, visualized using potassium permanganate stain. NMR spectra 
were acquired on a Varian – NMR 500 MHz instrument. Chemical shift values are expressed in 
ppm and residual solvent signals were used as references: CDCl3 (7.26 ppm for 1H and 77.16 
ppm for 13C), D2O (4.79 ppm for 1H). IR data was obtained through PerkinElmer Frontier IR 
Spectrometer.  
 
 
1-O-methyl-2,3-O-isopropylidene-D-ribofuranoside (18). 
Compound 18 was prepared from D-ribose according to literature procedures.55 D-ribose (1.0 g, 
6.7 mmol) was dissolved in a 8.6 mL solution of 1:1 methanol:acetone.  Approximately 0.15 mL 
of concentrated HCl was added dropwise before the reaction was heated to reflux for 90 min.  
The reaction was monitored by TLC (2:1 EtOAc:hexanes) and allowed to cool to room 
temperature upon consumption of starting material.  The reaction mixture was neutralized with 
pyridine and concentrated by rotary evaporation.  The crude material was partitioned between 
HO
O
OO
OMe
18
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ethyl acetate (10 mL) and water (20 mL).  The aqueous layer was extracted with three portions 
of ethyl acetate (10 mL), and the organic layers were combined and washed with saturated 
aqueous CuSO4 (20 mL), two portions of dH2O (15 mL), one portion of brine (10 mL), and dried 
over MgSO4.  After filtration, the product was concentrated by rotary evaporation to yield a light 
blue oil (0.69 g, 3.4 mmol, 51%). 1H NMR (500 MHz, CDCl3) δ 4.90 (s, 1H), 4.77 (d, J = 5.9 Hz, 
1H), 4.52 (d, J = 5.9 Hz, 1H), 4.36 (t, J = 2.9 Hz, 1H), 3.69 – 3.60 (m, 1H), 3.55 (ddd, J = 12.7, 
10.4, 3.5 Hz, 1H), 3.37 (s, 3H), 3.14 (d, J = 10.1 Hz, 1H), 1.42 (s, 3H), 1.25 (s, 3H) ppm. Small 
impurities include ethyl acetate and water from workup.  Data are consistent with published 
report.56  
 
N,N’-Di(tert-butoxycarbonyl)-L-homocystine, bis(tert-butyl) ester (26). 
Modification of published procedures.57,31  L-homocystine (0.27 g, 1.0 mmol) was dissolved in 
dioxane (8 mL) and 10% sodium carbonate solution (9 mL).  Reaction mixture was cooled to     
0 °C and di-tert-butyl dicarbonate (0.48 g, 2.2 mmol) was added.  The reaction mixture was 
stirred overnight at room temperature.  Solution was adjusted to pH 4 with 10% citric acid and 
extracted with ethyl acetate (3 x 15 mL).  The organic fractions were combined and washed with 
brine (30 mL), dried over magnesium sulfate, then concentrated under reduced pressure to yield 
Boc protected L-homocystine (33), which was carried forward without further purification. Boc 
protected L-homocystine was dissolved in DCM (10 mL) and cooled to 0 °C. Reagent tert-butyl-
2,2,2-trichloroacetimidate (1.15 g, 5 mmol) was added in one portion and the reaction was 
allowed to warm to room temperature. After stirring overnight, the reaction mixture was cooled 
to low temperature (−80 °C), and the bulk of byproduct 2,2,2-tert-butyltrichloroacetimide 
removed by filtration. The crude material was concentrated to a thick yellow oil by rotary 
t-BuO
O
NH
S)2
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evaporation. Residual byproduct was removed by column purification to yield product 26 in 61% 
as white powder over two steps (0.36 g, 0.62 mmol). 1H NMR (500 MHz, CDCl3) δ 5.02 (d, J = 
8.0 Hz, 2H), 4.19 (s, 2H), 2.76 – 2.44 (m, 4H), 2.21 – 2.06 (m, 2H), 1.99 – 1.82 (m, 2H), 1.41 (s, 
18H), 1.38 (s, 18H).  NMR data is consistent with published reports.57 The solid powder is stable 
indefinitely at room temperature. 
 
 
 
1-O-methyl-2,3-O-isopropylidene-5-O-(p-toluenesulfonyl)-β-D-ribofuranoside (29).  
Compound 29 was prepared from protected ribose derivative 18 according to literature 
procedures.27 p-Toluenesulfonyl chloride (0.92 g, 4.8 mmol) was added to a stirred solution of 
the protected ribose derivative 18 (0.66 g, 3.2 mmol) in pyridine (4.3 mL) at 0 °C.  The reaction 
mixture was gradually warmed to room temperature and stirred for an additional 24 h, after 
which time monitoring by TLC (1:1 EtOAc/hexanes) revealed no visible starting material 
remaining, and the pyridine was co-evaporated with three portions of toluene (5 mL) by rotary 
evaporation.  The crude product was taken up in EtOAc (50 mL), washed with three portions of 
saturated aqueous NaHCO3 (20 mL), and one portion of brine (20 mL).  The organic layer was 
dried over MgSO4, filtered, and solvent was removed by rotary evaporation.  Product isolated as 
fibrous white crystals after recrystallization from cold ethanol (0.71 g, 1.9 mmol, 61%). 1H NMR 
(500 MHz, CDCl3): δ 7.74 (d, J = 8.2 Hz, 2H), 7.29 (d, J = 8.1 Hz, 2H), 4.86 (s, 1H), 4.53 (d, J = 
5.9 Hz, 1H), 4.46 (d, J = 5.9 Hz, 1H), 4.24 (t, J = 7.2 Hz, 1H), 4.02 – 3.82 (m, 2H), 3.17 (s, 3H), 
2.39 (s, 3H), 1.38 (s, 3H), 1.22 (s, 3H).  All analytical data are largely consistent with published 
reports.58  The solid product is stable indefinitely with refrigeration. 
TsO
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N-tert-Butoxycarbonyl-S-(5-deoxy-1-O-methyl-2,3-O-isopropylidene-d-ribofuranos-5-yl)-l-
homocysteine tert-butyl ester (30).   
Modification of published procedures.27,26 To disulfide 26 (0.36 g, 0.62 mmol) in DMF (6 mL) 
was added 0.62 mL of  ddH2O and tributylphosphine ( 0.14 g, 0.68 mmol) and stirred overnight. 
The reaction mixture was monitored for consumption of starting material by TLC (1:3 
EtOAc/hexanes). The reaction mixture was quenched with water (50 mL) and mixture was 
extracted with ethyl acetate (3 x 15 mL). The organic fractions were combined and washed with 
brine (2 x 15 mL), then dried over magnesium sulfate. After filtration through a plug of celite, the 
filtrate was concentrated with rotary evaporation and trace solvent was removed by high 
vacuum to constant mass to yield the thiol 27, which was used without further purification. 
Crude thiol was then dissolved in THF (15 mL) and cooled to 0 °C. n-BuLi (1.6 M in hexane, 0.6 
mL, 0.93 mmol) was added and the mixture was stirred for ten minutes.  Tosylated ribose 
derivative 29 (0.22 g, 0.62 mmol) was added and reaction was stirred overnight at room 
temperature. The reaction was diluted with ethyl acetate (50 mL), washed with water (50 mL), 
then brine (50 mL), dried over magnesium sulfate, then concentrated in vacuo.  The resulting 
residue was dissolved in THF (3 mL), 2 µL of concentrated sulfuric acid and 2 µL of water were 
added and mixture was stirred for two hours.  Aqueous ammonium bicarbonate (10%, 10 mL) 
and ethyl acetate (50 mL) was added to the solution and the layers were separated. The organic 
layer was washed with brine, dried over magnesium sulfate, then concentrated via rotary 
evaporation to afford a crude yellow oil.  Silica gel flash column chromatography of the crude 
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material in 1:3 EtOAc/hexanes provided protected SRH derivative 30 in 18% over two steps as 
a colorless oil (0.053 g, 0.11 mmol). 1H NMR (500 MHz, CDCl3) δ 5.02 (d, J = 8.3 Hz, 1H), 4.90 
(bs, 1H), 4.62 (d, J = 6.0 Hz, 1H), 4.53 (d, J = 5.9 Hz, 1H), 4.23-4.13 (m, 2H), 3.27 (s, 3H), 2.69 
(dd, J = 13.5, 6.1 Hz, 1H), 2.59 – 2.44 (m, 3H), 2.01 (d, J = 9.5 Hz, 1H), 1.88 – 1.76 (m, 1H), 
1.41 (s, 3H), 1.40 (s, 9H), 1.38 (s, 9H), 1.25 (s, 3H). Includes 20% impurity and residual ethyl 
acetate solvent.  
 
 
S-D-Ribosyl-L-homocysteine, trifluoroacetic acid salt (SRH·TFA).  
Modification of published procedure for a similar compound.11 Protected SRH derivative 30 (52 
mg, 0.11 mmol) was dissolved in anisole (1 mL), water (1 mL) was added, and the solution was 
cooled to 0 °C.  TFA (3 mL) was added and reaction was stirred for 6 hours.  Product was 
concentrated to near dryness with rotary evaporator, then dissolved in water (2 mL), and 
washed with three 2 mL portions of DCM.  Aqueous layer was lyophilized to yield SRH·TFA as a 
clear oil/white solid (Quant., 42 mg, 0.11 mmol) 1H NMR (500 MHz, D2O) δ 5.40 (d, J = 4.0 Hz, 
0.6H), 5.25 (s, 1H), 4.30 – 4.13 (m, 4H), 4.12 – 3.97 (m, 2.5H), 3.11 – 2.88 (m, 1H), 2.88 – 2.68 
(m, 5H), 2.4 – 2.16 (m, 4H). Isolated as a mixture of α and β anomers. 1H NMR spectral data 
are largely consistent with a published report.24 
 
 
General procedure for chloroformate esterification of N-tert-Butoxycarbonyl-L-
homocystine  
Application of published procedure for amino acids to L-homocystine derivatives.29 N,N’-Di(tert-
butoxycarbonyl)-L-homocystine 33 (refer to procedure for compound 26) was stirred into DCM 
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(0.2 mM) and dissolved upon addition of triethylamine (2.1 equiv).  The reaction was cooled to  
0 °C before addition of the appropriate chloroformate reagent (2.1 equiv).  After ten minutes of 
stirring, DMAP (0.2 equiv) was added, and the reaction was allowed to stir overnight.  The 
reaction mixture was then diluted with DCM (6x volume) and washed with saturated sodium 
bicarbonate (0.6x volume), 0.1 M hydrochloric acid (0.6x volume), and brine (0.6x volume).  The 
aqueous washes were combined and extracted with DCM (1x volume).  The organic layers was 
dried over magnesium sulfate and concentrated to dryness before recrystallization. 
 
 
N,N’-Di(tert-butoxycarbonyl)-L-homocystine, bis(ethyl) ester (34).	
Using the general procedure for chloroformate esterification of N-tert-butoxycarbonyl-L-
homocystine, using ethyl chloroformate. Recrystallization from hot ethanol afforded compound 
34 as a white solid (127 mg, 27% yield). 1H NMR (500 MHz, CDCl3): δ = 5.13 (bs, 2H), 4.37 (bs, 
2H), 4.21 (q, J = 7.1 Hz, 4H), 2.78 – 2.65 (m, 4H), 2.24 (bs, 2H), 2.07 – 1.94 (m, 2H), 1.45 (s, 
18H), 1.29 (t, J = 7.1 Hz, 6H) ppm. NMR data consistent with published report.59	
 
N,N’-Di(tert-butoxycarbonyl)-L-homocystine, bis(iso-butyl) ester (35).	
Using the general procedure for chloroformate esterification of N-tert-butoxycarbonyl-L-
homocystine, using iso-butyl chloroformate. Recrystallization from hot ethanol afforded 
compound 35 as white crystals (260 mg, 44% yield).  1H NMR (500 MHz, CDCl3): δ = 5.11 (d, J 
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= 8.5 Hz, 2H), 4.40 (s, 2H), 4.03 – 3.86 (m, 4H), 2.73 – 2.65 (m, 4H), 2.31 – 2.20 (m, 2H), 1.99 
(ddt, J = 26.6, 13.3, 7.0 Hz, 4H), 1.45 (s, 18H), 0.95 (d, J = 6.7 Hz, 12H) ppm.  13C NMR (125 
MHz, CDCl3): δ = 172.1, 155.3, 80.0, 71.6, 52.6, 34.5, 32.7, 28.3, 27.7, 19.0 ppm. 
 
N,N’-Di(tert-butoxycarbonyl)-L-homocystine, bis(benzyl) ester (36)	 
Using the general procedure for chloroformate esterification of N-tert-butoxycarbonyl-L-
homocystine, using benzyl chloroformate. Recrystallization from hot ethanol afforded compound 
36 as white crystals (2.17 g, 52% yield).  TLC (1:3 EtOAc : hexanes): Rf 0.44. MP 123-124 oC. 
1H NMR (500 MHz, CDCl3): δ = 7.37 - 7.32 (m, 10H), 5.23 – 5.13 (m, 4H), 5.10 (d, J = 6.7 Hz, 
2H), 4.46 – 4.38 (m, 2H), 2.66 – 2.61 (m, 4H), 2.26 – 2.18 (m, 2H), 2.02 – 1.95 (m, 2H), 1.41 (s, 
18H) ppm. 13C NMR (125 MHz, CDCl3): δ = 171.9, 155.3, 135.2, 128.6, 128.5, 128.3, 80.1, 67.3, 
52.6, 34.4, 32.5, 28.3 ppm. IR (ATR): 3353, 2988, 1753, 1682, 1513 cm-1.  ESI-HRMS (m/z): 
[M+H]+ calcd for C32H44N2O8S2, 649.2612, found 649.2612.   
 
 
N-Benzyloxycarbonyl-L-homocystine tert-butyl ester (38). 
Application of published procedure for L-cystine to L-homocystine.60 L-homocystine (250 mg, 
0.93 mmol) was dissolved in a 9:1 water:THF solution (2.25 mL) under ambient conditions, 
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which was then was adjusted to pH 10 with 6 M NaOH and cooled to 0 °C.  Benzyl 
chloroformate (CBZ-Cl) (0.33 mL, 2.3 mmol) was added dropwise over 15 minutes and reaction 
was stirred while maintaining pH 10 with additional 6 M NaOH. After 3 h, the reaction was 
quenched with 4 mL of water and the pH was again readjusted to pH 10 with 6 M NaOH. The 
basic solution was washed with ether (3 X 10 mL) and then acidified to pH 2 with concentrated 
HCl, which precipitated a white solid. The precipitate was extracted with ethyl acetate (3 X 15 
mL), washed with pH 2 water (2 X 10) and brine (10 mL), dried over MgSO4, and concentrated 
using rotary evaporation to a white solid (N-benzyloxycarbonyl-L-homocystine, 37) which was 
used without further purification.  
Crude intermediate 37 (0.200 g, 0.37 mmol) was dissolved in DCM (3.5 mL). Tert-butyl-2,2,2-
trichloroacetimidate (0.41 g, 1.9 mmol) was added, and the reaction was allowed to stir 
overnight at room temperature. Solid byproduct was filtered off at low temperature and solvent 
was removed under reduced pressure. Silica gel flash column chromatography in 1:4 
EtOAc:hexanes afforded product 38 as a white solid in 67% yield over 2 steps. TLC (1:4 EtOAc: 
hexanes): Rf 0.44. MP 71-73 °C. 1H NMR (500 MHz, CDCl3): δ = 1H NMR (500 MHz, CDCl3, δ): 
7.36 – 7.32 (m, 10H), 5.44 (d, J = 7.0 Hz, 2H), 5.09 (s, 4H), 4.37 – 4.33 (m, 2H), 2.71-2.67 (m, 
4H), 2.22-2.17 (m, 2H), 2.07 – 2.01 (m, 2H), 1.46 (s, 18H) ppm. 13C NMR (125 MHz, CDCl3): δ = 
170.8, 155.9, 136.2, 128.5, 128.5, 128.2, 128.2, 128.1, 82.5, 67.0, 53.5, 34.4, 32.8, 28.0 ppm. 
IR (ATR): 3380, 2981, 1746, 1693, 1516 cm-1. ESI-HRMS (m/z): [M+H]+ calcd for C32H44N2O8S2, 
649.2612, found 649.2609.  
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N-2,2,2-Trichloroethoxycarbonyl-L-homocystine, tert-butyl ester (40). 
Procedure modified from that previously reported for similar compounds.61,31 L-homocystine 
(250 mg, 0.93 mmol) was dissolved in 1 M NaOH (2.7 mL) under ambient conditions, then the 
solution was cooled to 0 °C in an ice bath. 2,2,2-Trichloroethyl chloroformate (Troc-Cl) (0.53 mL, 
3.7 mmol) in dioxane (1.8 mL) was added dropwise at 0 °C, after which an additional portion of 
1 M NaOH (2.7 mL) was added dropwise. The reaction was allowed to slowly warm to room 
temperature and stir overnight, after which time dioxane was removed under reduced pressure 
and the remaining aqueous layer was washed with ether (3x10 mL) and acidified to pH 1-2 with 
concentrated HCl. Extraction with ethyl acetate (6x10 mL), followed by drying over sodium 
sulfate, and concentration under reduced pressure gave an oily solid (39) that was used without 
additional purification.  
Crude intermediate 39 (0.195 g, 0.32 mmol) was dissolved in DCM (3.25 mL). Tert-butyl-2,2,2-
trichloroacetimidate (0.370 g, 1.6 mmol) was added in one portion, and reaction was allowed to 
stir overnight at room temperature, at which time the solid byproduct was filtered off at after 
cooling to 0 °C. The filtrate was concentrated under reduced pressure to give a crude mixture 
which was then purified by silica gel flash column chromatography in 1:4 EtOAc:hexanes to 
afford product 40 as a sticky solid in 64% yield over two steps.  TLC (1:4 EtOAc:hexanes): Rf 
0.38; mp 75-77 oC. 1H NMR (500 MHz, CDCl3): δ = 5.65 (d, J = 7.2 Hz, 2H, NH), 4.79 (d, J = 
12.0 Hz, 2H), 4.69 (d, J = 12.1 Hz, 2H), 4.37 (dt, J = 7.2, 5.2 Hz, 2H), 2.71(m, 4H), 2.27 (m, 2H), 
2.09 (m, 2H), 1.49 (s, 18H) ppm. 13C NMR (125 MHz, CDCl3): δ = 170.3, 154.1, 95.4, 82.9, 74.6, 
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53.6, 34.3, 32.6, 28.0 ppm. IR (ATR): 3384, 2981, 1714, 1504 cm-1. ESI-HRMS (m/z): [M+H]+ 
calcd for C22H34Cl6N2O8S2, 728.9966, found 728.9954.  
 
 
N-Fluorenylmethyloxycarbonyl-L-homocystine, tert-butyl ester (42).  
Procedure modified from previously reported synthesis of amino acid derivatives. 62 ,31 L-
homocystine (500 mg, 1.86 mmol) was stirred in 6 mL of 10% Na2CO3 at 0 °C.  9-Fluorenmethyl 
chloroformate (Fmoc-Cl; 1.06 g, 4.1 mmol) was dissolved in dioxane (6 mL) and added 
dropwise.  The reaction mixture was stirred overnight at room temperature under ambient 
conditions. Upon consumption of starting material (monitored by TLC), the reaction was 
quenched into water (150 mL) and washed with ether (3x50 mL).  The aqueous layer was 
acidified to pH 2 with addition of concentrated HCl. Precipitate was extracted with ethyl acetate 
(3x50 mL), washed with water and brine, dried over MgSO4 and evaporated to afford a crude 
solid.  The solid was triturated in hexane to yield N-fluorenylmethyloxycarbonyl-L-homocystine 
(41) as white powder (0.899 g), which was used without further purification.  
 
Crude N-fluorenylmethyloxycarbonyl-L-homocystine 41 (0.899 g) was dissolved in DCM (15 mL) 
and tert-butyl-2,2,2-trichloroacetimidate (1.1 mL, 6.3 mmol) was added. After overnight stirring 
at room temperature, the reaction mixture was cooled to 0 °C and a solid byproduct was filtered 
off by running the mixture through a plug of celite.  The filtrate was concentrated under reduced 
t-BuO
O
HN
S)2
42
O
O
	 49 
pressure and the product was purified using silica gel flash column chromatography (1:4 
EtOAc:hexanes) to yield 42 as a greasy solid (0.451 g, 0.55 mmol) in 63% yield over two steps. 
TLC (1:4 EtOAc:hexanes): Rf 0.28. 1H NMR (500 MHz, CDCl3): δ = 7.75 (d, J = 7.5 Hz, 4H), 
7.57 (d, J = 7.2 Hz, 4H), 7.41 - 7.36 (m, 4H), 7.29 (m, 4H), 5.46 (d, J = 7.6 Hz, 2H), 4.38 – 4.32 
(m, 6H), 4.23 – 4.17 (m, 2H), 2.72 – 2.68 (m, 4H), 2.27 – 2.21 (m, 2H), 2.08 – 2.02 (m, 2H), 1.48 
(s, 18H) ppm. 13C NMR (125 MHz, CDCl3): δ = 170.9, 155.9, 143.9, 143.7, 141.3, 141.3, 127.7, 
127.0, 125.1, 125.1, 120.0, 119.9, 82.6, 67.0, 53.5, 47.2, 34.5, 32.7, 28.0 ppm. ESI-HRMS 
(m/z): [M+H]+ calcd for C46H52N2O8S2, 825.3238, found 825.3241.  
 
 
Ethyl-2-(4-methoxyphenylimino)acetate (69). 
Imine 69 was prepared according to published procedures.50  p-Anisidine (5.0 g, 41 mmol) was 
dissolved in 300 mL of ethyl acetate after which 4 Å molecular sieves were added.  Ethyl 
glyoxylate (50% in toluene, 8.2 mL, 41 mmol) was added to the solution and reaction was 
shaken vigorously and allowed to sit overnight.  Upon TLC (hexane:ethyl acetate, 1:1) showing 
consumption of starting material, the reaction mixture was filtered through a plug of celite.  The 
filtrate was concentrated in vacuo to yield imine 69 (99%) as a yellow oil of sufficient purity.  1H 
NMR (500 MHz, CDCl3): δ = 7.87 (s, 1H), 7.29 (d, J = 8.9 Hz, 2H), 6.86 (d, J = 8.9 Hz, 2H), 4.35 
(q, J = 7.1 Hz, 2H), 3.77 (s, 3H), 1.34 (t, J = 7.1 Hz, 3H) ppm.  13C NMR (125 MHz, CDCl3): δ = 
163.6, 160.5, 148.0, 141.4, 123.6, 114.5, 61.9, 55.5, 14.2 ppm. 
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Ethyl (2S,3S)-2-(4-methoxyphenylamino)-3-methyl-4-oxopentanoate (75). 
Compound 75 was prepared from imine 69 according to published procedures.49  L-Proline (1.65 
g, 0.35 equiv.), 4-butanone (80 mL, 22 equiv.) and 60 mL of dry DMF were stirred under argon.  
Imine 69 was dissolved in 20 mL of dry DMF and slowly added to reaction mixture.  Reaction 
was stirred overnight under argon.  L-Proline was removed via filtration, butanone and some 
DMF was removed via rotary evaporation.  Reaction was diluted with water (100 mL), extracted 
with ether (3x100mL) and washed with water (100 mL).  Organic layer was concentrated and 
purified via silica gel column chromatography (hexane:ethyl acetate, 85:15) to yield 75 as thick 
yellow oil (44%).  1H NMR (500 MHz, CDCl3): δ = 6.77 (d, J = 9.1 Hz, 2H), 6.65 (d, J = 8.8 Hz, 
2H), 4.31 (d, J = 5.8 Hz, 1H), 4.23 – 4.09 (m, 2H), 3.74 (s, 3H), 3.13 – 2.96 (m, 1H), 2.22 (s, 
3H), 1.36 – 1.12 (m, 6H) ppm.  13C NMR (125 MHz, CDCl3): δ = 209.1, 172.8, 153.1, 140.8, 
115.8, 114.8, 61.3, 59.6, 55.7, 49.2, 28.5, 14.1, 12.2 ppm. 
 
 
Ethyl (2S,3R)-2-(4-methoxyphenylamino)-3-methyl-4-oxopentanoate (76).  
Compound 76 was prepared according to published procedures.49  Column purified amine 75 
(1.2 g, 4.35 mmol) was dissolved in 0.5 mL of methyl tert-butyl ether (MTBE) under argon in 
glass vial. 1,5-Diazabicyclo[4.3.0]non-5-ene (DBN) (0.20 equiv.) was added and mixture was 
stirred for two hours at room temp.  MTBE was allowed to evaporate overnight slowly at room 
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temperature yielding solid cake.  Compound 76 was recrystallized with hot ethanol to yield white 
wispy crystals in 66% yield.  1H NMR (500 MHz, CDCl3): δ = 6.70 (d, J = 8.9 Hz, 2H), 6.59 (d, J 
= 8.9 Hz, 2H), 4.14 (d, J = 6.8 Hz, 1H), 4.12 – 4.01 (m, 2H), 3.67 (s, 3H), 2.96 (p, J = 7.0 Hz, 
1H), 2.16 (s, 3H), 1.27 – 1.01 (m, 6H) ppm.  13C NMR (126 MHz, CDCl3): δ = 209.5, 172.5, 
153.2, 140.6, 115.8, 114.8, 61.3, 60.6, 55.7, 49.4, 28.6, 14.1, 13.0 ppm.  IR (ATR): 3338.92, 
2975.10, 1731.57, 1701.86, 1514.83, 1235.18, 1161.52, 817.26 cm-1. 
 
 
Ethyl (2S,3S)-2-(4-methoxyphenylamino)-3-methyl-4-oxohexanoate (83). 
Compound 83 was prepared using a modified published procedure of similar compound.49  L-
Proline (0.39 g, 3.4 mmol), 2-pentanone (23 mL, 215 mmol) and DMF (20 mL) were stirred 
under argon at room temperature.  Imine 69 was dissolved in DMF (5 mL) and added dropwise 
over 5 minutes. Mixture was stirred overnight under argon. The reaction mixture was diluted 
with 75 mL of water and extracted with ether (2 x 75 mL) then washed with water (100 mL). 
Organic layer was dried over magnesium sulfate and condensed.  Compound was purified via 
silica gel column chromatography (hexane:ethyl acetate, 85:15) yielding 1.3 g (46%) dark yellow 
oil.  1H NMR (500 MHz, CDCl3) δ 6.76 (d, J = 8.5 Hz, 2H), 6.63 (d, J = 8.7 Hz, 2H), 4.21 (d, J = 
7.1 Hz, 1H), 4.19 – 4.10 (m, 2H), 3.74 (s, 3H), 2.95 – 2.90 (m, 1H), 2.22 (s, 3H), 1.90 – 1.81 (m, 
1H), 1.78 – 1.71 (m, 1H), 1.60 (q, J = 7.3 Hz, 1H), 1.21 (t, J = 7.3 Hz, 3H), 0.93 (t, J = 7.8 Hz, 
3H). 13C NMR (125 MHz, CDCl3) δ 209.5, 172.8, 153.0, 140.6, 115.5, 114.8, 61.3, 58.6, 56.6, 
55.7, 54.4, 45.2, 30.0, 21.0, 14.1 ppm. 2-pentanone starting material and ethyl-2-(4-
methoxyphenylimino)acetate (69) present in NMR. 
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(2S,3R)-Ethyl-2-amino-3-methyl-4-oxopentanoate (88). 
Compound 88 was prepared using a modification of published procedure.49  Protected amine 75 
(1g, 3.6 mmol) was dissolved in 1.75 mL of acetonitrile.  Reaction flask was placed into a 0 °C 
ice bath. A solution of ammonium nitrate (1.7 g) and CAN (0.2 g) in 10 mL water was added 
after reaction mixture had reached 0 °C. The reaction flask was then removed from the ice bath 
and heated to 35 oC for 3 hours. The reaction mixture was placed into a separatory funnel and 
washed with DCM (10x).  The aqueous phase was basified to pH 7 with addition of 2 N sodium 
carbonate.  Product was extracted with DCM (3x60 mL), the organic layer was then washed 
with water, dried over magnesium sulfate and concentrated in vacuo to yield 88 (155 mg, 26%) 
as a thin red oil.  1H NMR (500 MHz, CDCl3): δ= 4.19 (q, J = 7.3, 6.7 Hz, 2H), 3.89 (d, J = 4.7 
Hz, 1H), 2.97 – 2.91 (m, 1H), 2.23 (s, 3H), 1.28 (t, J = 7.2 Hz, 3H), 1.15 (d, J = 7.2 Hz, 3H) ppm. 
13C NMR (125 MHz, CDCl3): δ= 174.2, 61.2, 55.4, 49.7, 28.3, 14.2, 10.9 ppm. Isolated with a 
20% impurity and proton NMR contains residual DCM.  
 
 
Ethyl (tert-butoxycarbonyl)-C2-tosylglycinate (90). 
Compound 90 was prepared according to literature procedures.52 Tert-butyl carbamate (1.0 g, 
8.5 mmol), ethyl glyoxylate (3.5 mL, 17.1 mmol) and sodium p-toluenesulfinate (6.4 g, 25.6 
mmol) were combined at room temperature and 8.8 mL of 50% formic acid in water was added.  
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The reaction mixture was stirred for three hours.  The reaction mixture was quenched by 
trituration into ice water to yield white crystals that were filtered and washed with cold water to 
afford 90 as a white powder in 40% yield (1.2 g). 1H NMR (500 MHz, CDCl3): δ = 7.82 (d, J = 6.9 
Hz, 2H), 7.35 (d, J = 8.0 Hz, 2H), 5.76 (d, J = 10.2 Hz, 1H), 5.56 (d, J = 10.0 Hz, 1H), 4.38 – 
4.29 (m, 2H), 2.44 (s, 3H), 1.46 – 1.09 (m, 12H) ppm. 13C NMR (125 MHz, CDCl3): δ = 163.3, 
153.3, 145.6, 133.7, 129.6, 81.5, 73.4, 63.4, 28.0, 21.7, 14.0 ppm. 
 
 
Ethyl (2S,3R)-2-((tert-butoxycarbonyl)amino)-3-methyl-4-oxobutanoate (92). 
Compound 92 was prepared from 90 according to literature procedures.51 Modified proline 
catalyst 2-(bis(2,6-bis(trifluoromethyl)phenyl)((trimethylsilyl)oxy)methyl)pyrrolidine (67 mg, 20 
mol %)51 was stirred in chloroform (2.8 mL). Propionaldehyde (0.08 mL, 1.1 mmol) was added 
and the resulting mixture was stirred for five minutes at room temperature.  α−Amidosulfone 90 
(200 mg, 0.56 mmol) was added, followed by KF (0.16 g, 2.8 mmol).  The reaction mixture was 
stirred for 24 hours, then diluted with additional chloroform (2 mL) and flushed through a silica 
plug with 1:1 chloroform:ethyl acetate, then concentrated under vacuum and purified via silica 
gel column chromatography (hexane:ethyl acetate, 9:1) to yield 77% (112 mg) of 92. 1H NMR 
(500 MHz, CDCl3): δ = 9.64 (s, 1H), 5.29 (d, J = 8.7 Hz, 1H), 4.64 (dd, J = 8.8, 3.9 Hz, 1H), 4.22 
– 4.14 (m, 2H), 3.12 (s, 1H), 1.45 (s, 9H), 1.24 (t, J = 7.1 Hz, 3H), 1.17 (d, J = 7.4 Hz, 3H) ppm.  
13C NMR (125 MHz, CDCl3): δ = 201.6, 170.5, 155.6, 80.2, 61.9, 53.6, 48.9, 28.3, 14.0, 9.4 
ppm.		
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